Kukoamine B
Based on 1 publication(s) in Google Scholar
Kukoamine B, a spermine alkaloid, is a potent dual LPS and CpG DNA inhibitor with Kd values of 1.23 µM and 0.66 µM, respectively. Kukoamine B exerts anti-inflammatory, anti-diabetic, anti-oxidant, anti-osteoporotic and neuroprotective effects. Kukoamine B has the potential for the study of sepsis.
For research use only. We do not sell to patients.
- Purity: 99.87%
- CAS No.: 164991-67-7
- Formula: C28H42N4O6
- Molecular Weight:530.66
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) Kukoamine B
MoreAll DNA/RNA Synthesis Isoforms
More
Biological Activity
Kukoamine B (5-20 μM, 2 h) increases cell viability, and prevents plasma membrane from damaging in SH-SY5Y cells[2].
Kukoamine B (5-20 μM, 2 h) attenuates H2O2-induced Apoptosis and mitochondria membrane potential (MMP) loss in SH-SY5Y cells[2].
Kukoamine B (5-20 μM, 2 h) demonstrates anti-oxidative stress effects by modulating the MAPKs and PI3K-AKT signaling pathways in SH-SY5Y cells[2].
Kukoamine B (10-20 μM, 3 days) increases osteoblast differentiation and the mineralized nodule formation of preosteoblastic MC3T3-E1 cells[3].
Kukoamine B (50-200 μM, 12 h) is a dual inhibitor of LPS- and CpG DNA-induced TNF-a and IL-6 release from RAW 264.7 cells and murine peritoneal macrophages[4].
Kukoamine B (50-200 μM, 12 h) down-regulates two receptors (TLR4 and TLR9) and two important enzymes (iNOS and COX-2) mRNA expressions upregulated by LPS and CpG DNA in RAW 264.7cells[4].
Kukoamine B (0-200 μM, 30min-2 h) inhibits IkB-a and p38 phosphorylation and NF-kB activation induced by LPS and CpG DNA in RAW 264.7cells [4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:SH-SY5Y cells
-
Concentration:5, 10, 20 μM (H2O2, 100 μM, for another 12 h)
-
Incubation Time:2 h
-
Result:Prevented cell death and improved cell viability dose-dependently.
Lowered the LDH release.
Increased the activity of CAT, SOD, and GSH-Px, and reduced the MDA production.
-
Cell Line:SH-SY5Y cells
-
Concentration:5, 10, 20 μM (H2O2, 100 μM, for another 12 h)
-
Incubation Time:2 h
-
Result:Decreased total apoptotic cells and late apoptotic cells.
-
Cell Line:SH-SY5Y cells
-
Concentration:5, 10, 20 μM (H2O2, 100 μM, for another 12 h)
-
Incubation Time:2 h
-
Result:Increased the fluorescence intensity of Rho (Rhodamine) 123.
Decreased the ROS production.
-
Cell Line:SH-SY5Y cells
-
Concentration:5, 10, 20 μM (H2O2, 100 μM, for another 12 h)
-
Incubation Time:2 h
-
Result:Restored the mitochondria function via inhibiting the ratio of Bcl-2/Bax.
Decreased cytochromec, caspase-3, caspase-9, p-p38, p-ERK and p-JNK expression.
Increased p-AKT expression.
-
Cell Line:RAW 264.7 cells
-
Concentration:0, 100, 200 μM
-
Incubation Time:12 h
-
Result:Down-regulated the mRNA expression of two receptors (TLR4 and TLR9) and two important enzymes (iNOS and COX-2).
-
Cell Line:RAW 264.7 cells
-
Concentration:0, 100, 200 μM
-
Incubation Time:30 min-2 h
-
Result:Suppressed the IkB-a and p38 phosphorylation as well as the degradation of IkB-a.
Kukoamine B (2, 5 mg/kg, p.o., daily, 12 weeks) demonstrates the anti-osteoporotic effects in ovariectomized (OVX) mice[3].
Kukoamine B (1.25-60 mg/kg, i.v., only one injection or very 8 h for 3 days) protects mice challenged with E. coli and reduces the circulatory levels of LPS and TNF-a in sepsis model mice[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male, 4-week old db/db mice (BKS.Cgm+/+Leprdb/J) and wildtype (WT) mice (C57BLKS/J-m+/+ db). A spontaneous type 2 diabetic animal model[1].
-
Dosage:20, 50 mg/kg
-
Administration:i.g., daily, 9 weeks
-
Result:Successfully controlled the augment of blood glucose with age increase.
Reduced levels of 29 inflammatory markers such as IL-2, IL-3, IL-4, IL-5, IL-6, IL-7 and IL8.
-
Animal Model:Seven-week-old female ddy mice underwent either an ovariectomy or sham-operated surgery[3].
-
Dosage:2, 5 mg/kg
-
Administration:p.o., daily, 12 weeks
-
Result:Inhibited the OVX-induced BMD loss in the right femur bone and restored the impaired bone structural properties of BV/TV, Tb.Th, Tb.N, and Tb.Sp.
-
Animal Model:Kunming (KM) mice, 4–6 weeks old, 18–20 g, male and female in equal number. Mice were injected with heat-killed E. coli (EC, 1.0 * 1011 CFU•kg-1) in order to establish the sepsis model.[4].
-
Dosage:1.25, 2.5, 5, 10, 15, 30, 60 mg/kg
-
Administration:80 mice (15, 30, 60 mg/kg), i.v., only one injection; 100 mice (1.25, 2.5, 5 mg/kg), i.v., every 8 h for 3 days; 96 mice, (60 mg/kg), i.v., once at 0, 2, 4, 6, 8 h after injection of EC.
-
Result:Significantly decreased the mortality rate from 87.5% to 62.5%, 62.5%, or 37.5% (15, 30, 60 mg/kg).
Decreased the mortality rate from 95% to 65%, 60% and 45% (1.25, 2.5 and 5 mg/kg).
Decreased the circulatory LPS and TNF-a levels in a time-dependent manner.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 164991-67-7
-
Appearance Solid
-
Molecular Weight 530.66
-
Formula C28H42N4O6
-
Color White to off-white
-
SMILES
O=C(N(CCCN)CCCCNCCCNC(CCC1=CC=C(O)C(O)=C1)=O)CCC2=CC=C(O)C(O)=C2
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
TrxR2 Lactylation Facilitates Mitochondrial Protection and Endothelial Ferroptosis Resistance in Diabetic Cardiomyopathy. [Abstract]2026 Apr;13(22):e21997. PMID: 41704008
Solvent & Solubility
H2O : 62.5 mg/mL (117.78 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 50 mg/mL (94.22 mM); Clear solution; Need ultrasonic
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Li YY, et al. A Metabolomics Approach to Investigate Kukoamine B-A Potent Natural Product With Anti-diabetic Properties. Front Pharmacol. 2019 Jan 22;9:1575. [Content Brief]
[2]. Hu XL, et al. Neuroprotective effects of Kukoamine B against hydrogen peroxide-induced apoptosis and potential mechanisms in SH-SY5Y cells. Environ Toxicol Pharmacol. 2015 Jul;40(1):230-40. [Content Brief]
[3]. Park E, et al. Anti-Osteoporotic Effects of Kukoamine B Isolated from Lycii Radicis Cortex Extract on Osteoblast and Osteoclast Cells and Ovariectomized Osteoporosis Model Mice. Int J Mol Sci. 2019 Jun 6;20(11):2784. [Content Brief]
[4]. Liu X, et al. Kukoamine B, a novel dual inhibitor of LPS and CpG DNA, is a potential candidate for sepsis treatment. Br J Pharmacol. 2011 Mar;162(6):1274-90. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 1.8844 mL | 9.4222 mL | 18.8445 mL | 47.1111 mL |
| 5 mM | 0.3769 mL | 1.8844 mL | 3.7689 mL | 9.4222 mL | |
| 10 mM | 0.1884 mL | 0.9422 mL | 1.8844 mL | 4.7111 mL | |
| 15 mM | 0.1256 mL | 0.6281 mL | 1.2563 mL | 3.1407 mL | |
| 20 mM | 0.0942 mL | 0.4711 mL | 0.9422 mL | 2.3556 mL | |
| 25 mM | 0.0754 mL | 0.3769 mL | 0.7538 mL | 1.8844 mL | |
| 30 mM | 0.0628 mL | 0.3141 mL | 0.6281 mL | 1.5704 mL | |
| 40 mM | 0.0471 mL | 0.2356 mL | 0.4711 mL | 1.1778 mL | |
| 50 mM | 0.0377 mL | 0.1884 mL | 0.3769 mL | 0.9422 mL | |
| 60 mM | 0.0314 mL | 0.1570 mL | 0.3141 mL | 0.7852 mL | |
| 80 mM | 0.0236 mL | 0.1178 mL | 0.2356 mL | 0.5889 mL | |
| 100 mM | 0.0188 mL | 0.0942 mL | 0.1884 mL | 0.4711 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.